Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
25 studies found for:    "Amyloid neuropathy"
Show Display Options
RSS Create an RSS feed from your search for:
"Amyloid neuropathy"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of SOM0226 in Familial Amyloid Polyneuropathy
Condition: Familial Amyloid Polyneuropathy (FAP)
Intervention: Drug: SOM0226
2 Completed
Has Results
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
Condition: Transthyretin Familial Amyloid Polyneuropathy
Intervention: Drug: tafamidis
3 Completed
Has Results
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
Conditions: Familial Amyloid Polyneuropathy;   ATTR-PN
Intervention: Drug: Fx-1006A
4 Not yet recruiting Prevalence of Amyloidosis and Carpal Tunnel
Condition: Amyloid Neuropathy, Carpal Tunnel
Intervention:
5 Completed
Has Results
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Condition: Familial Amyloid Polyneuropathy
Interventions: Drug: Fx-1006A;   Drug: Placebo
6 Active, not recruiting Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy
Conditions: FAP;   Familial Amyloid Polyneuropathy;   TTR;   Transthyretin;   Amyloidosis
Interventions: Drug: IONIS-TTR Rx;   Drug: Placebo
7 Enrolling by invitation Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Conditions: FAP;   Familial Amyloid Polyneuropathy;   TTR;   Transthyretin;   Amyloidosis
Intervention: Drug: IONIS-TTR Rx
8 Completed Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
Conditions: Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP);   Transthyretin Cardiomyopathy (TTR-CM);   Familial Amyloid Cardiomyopathy;   Senile Systemic Amyloidosis (SSA)
Intervention: Other: No drug
9 Completed The Effect of Diflunisal on Familial Amyloidosis
Conditions: Familial Amyloid Polyneuropathy;   Familial Amyloidosis
Interventions: Drug: diflunisal;   Other: placebo
10 Active, not recruiting The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
Conditions: Transthyretin (TTR)-Mediated Amyloidosis;   Familial Amyloidotic Polyneuropathy (FAP);   ATTR Amyloidosis;   Familial Amyloid Neuropathies
Intervention: Drug: Revusiran (ALN-TTRSC)
11 Recruiting Biomarker for Patients With Transthyretin-Related Familial Amyloidotic Polyneuropathy
Conditions: Metabolic Diseases;   Amyloid Neuropathies;   Amyloidosis, Familial;   Polyneuropathies
Intervention:
12 Active, not recruiting APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
Conditions: TTR-mediated Amyloidosis;   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Familial Amyloid Polyneuropathies;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related
Interventions: Drug: patisiran (ALN-TTR02);   Drug: Sterile Normal Saline (0.9% NaCl)
13 Available Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Conditions: TTR-mediated Amyloidosis;   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Familial Amyloid Polyneuropathies;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related
Intervention: Drug: patisiran (ALN-TTR02)
14 Active, not recruiting ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC);   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related;   Familial Transthyretin Cardiac Amyloidosis
Interventions: Drug: Revusiran (ALN-TTRSC);   Drug: Sterile Normal Saline (0.9% NaCl)
15 Completed The Effect of Diflunisal on Familial Transthyretin Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Diflunisal
16 Completed Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
Condition: Transthyretin Amyloidosis
Intervention: Drug: Doxycycline + Tauroursodeoxycholic acid
17 Recruiting Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)
Conditions: Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
18 Not yet recruiting Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy
Conditions: Polyneuropathies;   Amyloidosis;   Amyloid Neuropathies;   Amyloidosis, Familial;   Metabolic Diseases
Intervention:
19 Completed
Has Results
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
Condition: Transthyretin-associated Amyloidosis With Polyneuropathy
Intervention: Drug: Fx-1006A
20 Completed Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis
Conditions: Transthyretin Amyloidosis;   Cardiomyopathy
Interventions: Drug: Doxycycline;   Drug: Ursodeoxycholic acid

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.